menu search

ZYME / Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings

Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings
Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. A significant pipeline, with partners helping to finance drug trials, is worthy of consideration. Read More
Posted: Apr 10 2023, 01:17
Author Name: Seeking Alpha
Views: 103024

ZYME News  

Zymeworks Announces Participation in Upcoming Investor Conferences

By GlobeNewsWire
November 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Zymeworks To Host Third Quarter 2023 Results Conference Call

By GlobeNewsWire
October 17, 2023

Zymeworks To Host Third Quarter 2023 Results Conference Call

VANCOUVER, British Columbia, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Adding Zymeworks To My Value Watchlist (Initial Buy Rating)

By Seeking Alpha
September 11, 2023

Adding Zymeworks To My Value Watchlist (Initial Buy Rating)

Zymeworks is a biotech company focused on developing therapies for hard-to-treat cancers. Its lead product, zanidatamab, has shown promising results i more_horizontal

Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 10, 2023

Zymeworks Inc. (ZYME) Q2 2023 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q2 2023 Earnings Call August 10, 2023 4:30 PM ET Company Participants Diana Papove - Director of Corporate Communication more_horizontal

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

By Zacks Investment Research
August 10, 2023

Zymeworks Inc. (ZYME) Reports Q2 Loss, Lags Revenue Estimates

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss more_horizontal

Zymeworks Announces Participation in Upcoming Investor Conference

By GlobeNewsWire
July 3, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

VANCOUVER, British Columbia, July 03, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Zymeworks Announces Participation in Upcoming Investor Conferences

By GlobeNewsWire
June 1, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, more_horizontal

Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 8, 2023

Zymeworks Inc. (ZYME) Q1 2023 Earnings Call Transcript

Zymeworks Inc. (NASDAQ:ZYME ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Kenneth Galbraith - Chairman, Chief Executi more_horizontal


Search within

Pages Search Results: